Please login to the form below
breakthrough designation
This page shows the latest breakthrough designation news and features for those working in and with pharma, biotech and healthcare.
ASCO: Bavencio boosts survival post-chemo in bladder cancer
The FDA awarded breakthrough designation to the drug for first-line maintenance use in April, and the investigators reckon the drug could be a ‘game changer’ in this setting.
Latest news
-
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win
breakthrough designation from the FDA for use in children.
-
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
Potential treatment for patient group with no FDA-approved drugs. Johnson and Johnson has been awarded a breakthrough designation from the FDA for a bispecific antibody for lung cancer that combines ... Last year, Spectrum Pharmaceuticals reported some
-
Trevena gets second go at FDA approval for pain drug
Rubbing further salt into the wounds, the FDA then withdrew its breakthrough designation for oliceridine last year, saying that the phase 3 data for Trevena’s drug weren’t strong enough
-
BMS unveils long-term results for Opdivo in kidney cancer
respectively. Initial results from the CheckMate-025 study formed the basis of an FDA breakthrough designation for Opdivo in this setting, and the subsequent approval for the checkpoint inhibitor in advanced
-
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
All three of the PARP inhibitors have been awarded a breakthrough designation from the FDA in prostate cancer, reflecting the urgent need for new therapies to treat the disease.
More from news
Approximately 1 fully matching, plus 147 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Nine US, four EU and one Japanese Orphan Drug designation. Four US Breakthrough Therapy designations. ... This determination may mean that instead of expedited review because of AR-101’s Breakthrough Therapy designation, the filing may be given a
-
Drug launches to watch in 2019
Analysts say the market could eventually be worth $4.8bn annually. The FDA granted AR101 Fast Track Designation for peanut allergy in September 2014 and Breakthrough Therapy Designation for peanut allergy ... Upadacitinib is already in a phase 3 trial in
-
Bluebird Bio: on the cusp of a gene therapy revolution
Bluebird’s four breakthrough candidates. In addition to the two LentiGlobin-based treatments, the company also has its Lenti-D product for patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and ... There is no question that these
-
Deal Watch February 2017
IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior therapies for metastatic disease and also has Fast Track status and orphan designation
-
Deal Watch January 2016
32, 000. Seres Therapeutics/ Nestle Health Science. Collaboration. Rights to market products including SER 262 (p1 for Clostridium difficile), 287, 301 and 109 (SER 109 has breakthrough therapy designation); includes $120m
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
